Waters Corporation Schedules Second Quarter 2026 Earnings Conference Call
MILFORD, Mass., July 2, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) will hold its Q2 2026 financial results conference call on Tuesday, August 4, 2026, at 8:00 a.m.
WAT - Waters Corporation
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$400.78
DETAILS
HIGH:
$435.00
LOW:
$350.00
MEDIAN:
$400.00
CONSENSUS:
$400.78
UPSIDE:
6.47%
Stock News
IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine
LONDON--(BUSINESS WIRE)--IMU Biosciences, a biotechnology company decoding the immune system to pioneer a paradigm shift in how we understand, diagnose, and treat disease, and Waters Corporation (NYSE: WAT) today announced a strategic partnership to accelerate the development of IMU's next-generation AI-powered High Definition (HD) Immunology platform.The partnership brings together Waters Biosciences' advanced flow cytometry and single-cell technologies,1 including BD FACSDiscover Cell Analyzer.
Waters Launches Coin Cell Differential Scanning Calorimeter (DSC) to Advance Battery Safety with Integrated Thermal, Evolved Gas, and Electrochemical Analysis
Integrates heat flow, evolved gas, and electrochemical analysis in a single experiment, enabling earlier insights into thermal runaway. Unique whole-cell design eliminates cell teardown, reducing sample preparation time by >90%.
Waters Launches Industry-First Reversed-Phase Bioseparation Columns to Deliver Up to 3x Faster GLP-1 Characterization and 2x Faster LNP Component Analysis
Faster run times for GLP-1, insulin, and LNP drug substance testing accelerates biopharmaceutical development timelines and reduces production bottlenecks. Delivers up to 2x increase in resolving power and sensitivity to identify and track low-level impurities for improved regulatory readiness.
Why Is Waters (WAT) Up 8.7% Since Last Earnings Report?
Waters (WAT) reported earnings 30 days ago. What's next for the stock?
Waters Corporation (WAT) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Waters Corporation (WAT) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Waters Announces FDA 510(k) Clearance of BD BACTEC FXI Culture System, Enabling Broader Access to Bloodstream Infection Diagnostics
FDA 510(k)-cleared BD BACTEC™ FXI Culture System now available to U.S. market, enabling broader access to confident bloodstream infection diagnostics. Achieves a 3-hour faster time to detection (~15% reduction) versus the prior-generation system, per clinical study data, enabling earlier targeted sepsis prevention.
Waters Introduces Unrivaled Sensitivity and Speed to Benchtop HRMS with Xevo MRT P10 MS, Accelerating Multiomics Research
Delivers up to 20x improvement in MS/MS sensitivity and 2x faster acquisition speeds, enabling deeper biological insight for next-generation multiomics, therapeutic, and high-throughput workflows. Identifies up to 40% more lipids by LC‑MS/MS than the leading alternative benchtop high‑resolution mass spectrometer, advancing lipidomics research and disease understanding.
Waters Unveils Cyclic IMS P20 MS: The New Benchmark in Structural and Spatial Omics
>10x step-change in MS/MS sensitivity paired with multipass Cyclic™ Ion Mobility Spectrometry (IMS) reveals subtle biological differences for earlier, previously unattainable detection of disease signals. 50% extended upper mass range and comprehensive suite of structural tools advance the development of next-generation biotherapeutics.
Carnival: Calm Waters Despite Fuel Price Headwinds
Carnival has stabilized after a strong rally, with shares flat since August amid solid fundamentals and macro headwinds. Carnival reported strong Q1 2026 results: 6% revenue growth, 11% operating earnings growth, and adjusted EPS up to $0.20, despite higher share count. 85% of 2026 capacity is already sold, dividend reinstated at $0.15 per quarter, and further deleveraging is underway, though growth is slowing.
Waters Corporation to Present at the Jefferies Global Healthcare Conference
MILFORD, Mass., May 18, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D.
Understanding Waters (WAT) Reliance on International Revenue
Examine the evolution of Waters' (WAT) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
WAT Q1 Earnings Beat Estimates, BD Acquisition Aids Revenues
Waters crushes Q1 2026 estimates as revenues surge 91.5%; newly acquired BD units top targets early, and 2026 guidance moves higher.
Conrad Industries Is Worth The Volatile Waters The Industry Faces
Conrad Industries is a small-cap shipbuilder trading at a discount to heavy equipment peers, supported by recent revenue and profitability improvements. CNRD shifted from a $27 million net loss in 2023 to a $19.9 million net profit in 2024, with adjusted operating cash flow also turning positive. Despite a declining backlog and order softness, especially in energy, management remains cautiously optimistic for 2026 due to government and infrastructure demand.
Waters Corporation (WAT) Q1 2026 Earnings Call Transcript
Waters Corporation (WAT) Q1 2026 Earnings Call Transcript
Waters raises annual profit forecast as biosciences unit drives growth
Lab equipment maker Waters raised its annual profit forecast on Tuesday after beating quarterly estimates, driven by robust demand for drug development tools and the strong performance of its biosciences and diagnostics unit, acquired last year.
Waters (WAT) Beats Q1 Earnings and Revenue Estimates
Waters (WAT) came out with quarterly earnings of $2.7 per share, beating the Zacks Consensus Estimate of $2.31 per share. This compares to earnings of $2.25 per share a year ago.
Waters Corporation (NYSE: WAT) Reports First Quarter 2026 Financial Results
First Quarter 2026 Highlights Total reported revenue of $1.267 billion exceeded the high end of the guidance range by $56 million, driven by strong outperformance in both organic revenue and the acquired businesses. Organic revenue grew 13% as reported and 11% in constant currency, exceeding the high end of the constant currency growth guidance range by 200 basis points – led by high-single-digit instrument growth and mid-teens chemistry growth within the Analytical Sciences Division.
Teleflex (TFX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Teleflex (TFX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Waters (WAT) Beat Estimates Again in Its Next Earnings Report?
Waters (WAT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Price Targets
Waters price target raised to $390 from $350 at Morgan Stanley
$390.00
(was $368.13)
Kallum Titchmarsh
·
Morgan Stanley
Waters initiated with an Outperform at RBC Capital
$435.00
(was $368.13)
RBC Capital
Waters price target raised to $410 from $380 at Evercore ISI
$410.00
(was $375.38)
Evercore ISI
Waters initiated with a Neutral at Piper Sandler
$400.00
(was $363.18)
Piper Sandler
Waters price target raised to $435 from $415 at HSBC
$435.00
(was $371.93)
HSBC
Waters price target raised to $350 from $330 at Deutsche Bank
$350.00
(was $351.33)
Deutsche Bank
Waters price target raised to $425 from $400 at Barclays
$425.00
(was $349.53)
Barclays
Waters price target raised to $375 from $330 at UBS
$375.00
(was $352.64)
UBS
Waters price target raised to $387 from $362 at Baird
$387.00
(was $342.75)
Robert W. Baird
Waters price target lowered to $350 from $423 at Morgan Stanley
$350.00
(was $333.33)
Morgan Stanley
Waters price target lowered to $370 from $395 at UBS
$370.00
(was $327.59)
UBS
Waters price target lowered to $363 from $398 at Baird
$363.00
(was $326.16)
Robert W. Baird
Waters reinstated with an Overweight at Barclays
$400.00
(was $328.14)
Barclays
Waters initiated with a Buy at Guggenheim
$440.00
(was $394.97)
Subbu Nambi
·
Guggenheim
Waters price target raised to $415 from $385 at Wells Fargo
$415.00
(was $385.33)
Brandon Couillard
·
Wells Fargo
Wolfe Research Upgrades Waters Corp. (WAT) to Outperform
$480.00
(was $386.16)
Doug Schenkel
·
Wolfe Research
Waters initiated with an Equal Weight at Morgan Stanley
$423.00
(was $397.79)
Morgan Stanley
Waters initiated with a Buy at Rothschild & Co Redburn
$390.00
(was $318.35)
Natalya Davies
·
Redburn Partners
Waters price target lowered to $315 from $375 at Deutsche Bank
$315.00
(was $281.19)
Deutsche Bank
Waters price target lowered to $385 from $435 at Jefferies
$385.00
(was $285.59)
Jefferies